Japanese Patent 5443763 claims new pharmaceutical formulations of sapacitabine, while Patent 5457196 claims methods of treating cancer comprising sapacitabine in combination with histone deacetylase (HDAC) inhibitors. According to
Both the companies have not disclosed the financial details of the agreement, which is for an initial term of three years. Cardiome chief commercial officer Karim Lalji said
Under the collaboration, new gene therapy vectors and proprietary molecules will be discovered and developed using the Avalanche Ocular BioFactory, an adeno-associated virus (AAV)-based, proprietary, next-generation platform for
The Phase III trial results demonstrated that patients administered with pasireotide long-acting release (LAR) achieved greater disease control when compared to continued treatment with the standard somatostatin analogue
The Phase Ib/IIa study will evaluate the safety, tolerability and pharmacokinetics of a single ascending dose of COVA322, a bispecific TNF/IL-17A inhibitor. The randomized, double-blind, placebo-controlled will enroll
Novogen and Genea Biocells have already conducted preliminary research and found that super-benzopyrans appear to be effective at promoting the ‘normalization’ of stem cells associated with some forms
Currently, OncoMed is conducting a Phase Ib clinical trial of demcizumab in combination with Abraxane (nab-paclitaxel) and gemcitabine in first-line Stage IV pancreatic cancer patients. OncoMed chairman and
The study is aimed at evaluating numerous clinical factors and the microbiome in a select cohort of approximately 900 individuals with varying metabolic phenotypes to better understand the
Study site for this first enrollment is Malaysia. The Phase III study has been designed to evaluate the safety, efficacy and pharmacokinetics of its rVIII-SingleChain for the treatment
Ruthigen plans to begin its combined Phase I/II clinical trial for its lead drug candidate RUT58-60 as early as July 2014. The study may be conducted at up
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.